Ordering Recommendation

Aid in diagnosis of combined motor/sensory neuropathy when malignancy, other than plasma cell dyscrasia, is suspected.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Plasma, CSF, or other body fluids. Contaminated, heat-inactivated, hemolyzed, severely icteric, or lipemic specimens.

Remarks
Stability

Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 1 year

Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot

Performed

Thu

Reported

1-9 days

Reference Interval

Test Number
Components
Reference Interval
  Asialo-GM1 Antibodies, IgG/IgM 0-50 IV
  GM1 Antibodies, IgG/IgM 0-50 IV
  GD1a Antibodies, IgG/IgM 0-50 IV
  GD1b Antibodies, IgG/IgM 0-50 IV
  GQ1b Antibodies, IgG/IgM 0-50 IV
  SGPG Antibody, IgM Less than 1.00 IV
  MAG Antibody, IgM Elisa Less than 1000 TU
  Purkinje Cell/Neuronal Nuclear IgG Scrn None Detected

Interpretive Data

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.


Component Interpretation
Asialo-GM1 Antibodies, IgG/IgM 29 IV or less
30-50 IV
51-100 IV
101 IV or greater
Negative
Equivocal
Positive
Strong Positive
GM1 Antibodies, IgG/IgM 29 IV or less
30-50 IV
51-100 IV
101 IV or greater
Negative
Equivocal
Positive
Strong Positive
GD1a Antibodies, IgG/IgM 29 IV or less
30-50 IV
51-100 IV
101 IV or greater
Negative
Equivocal
Positive
Strong Positive
GD1b Antibodies, IgG/IgM 29 IV or less
30-50 IV
51-100 IV
101 IV or greater
Negative
Equivocal
Positive
Strong Positive
GQ1b Antibodies, IgG/IgM 29 IV or less
30-50 IV
51-100 IV
101 IV or greater
Negative
Equivocal
Positive
Strong Positive

Compliance Category

Laboratory Developed Test (LDT)

Note

Purkinje Cell (PCCA) antibody and Neuronal Nuclear (ANNA) antibody IgG are screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, and Tr/DNER) IgG by Immunoblot will be added. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, and Tr/DNER) IgG by Immunoblot will be added. Additional charges apply.

Hotline History

N/A

CPT Codes

83516 x7; 86255; if reflexed add 84182 x4 and/or 86256

Components

Component Test Code* Component Chart Name LOINC
0051034 Asialo-GM1 Antibodies, IgG/IgM 88723-2
0051035 GM1 Antibodies, IgG/IgM 31500-2
0051037 GD1a Antibodies, IgG/IgM 88724-0
0051038 GD1b Antibodies, IgG/IgM 88730-7
0051039 GQ1b Antibodies, IgG/IgM 88729-9
0051284 SGPG Antibody, IgM 31666-1
0051285 MAG Antibody, IgM Elisa 17314-6
2007962 Purkinje Cell/Neuronal Nuclear IgG Scrn 61177-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Motor and Sensory Neuropathy Evaluation with Reflex to Titer and Neuronal Immunoblot